Elevance Health Future Growth

Future criteria checks 1/6

Elevance Health is forecast to grow earnings and revenue by 12.4% and 5.1% per annum respectively. EPS is expected to grow by 14.2% per annum. Return on equity is forecast to be 19.6% in 3 years.

Key information

12.4%

Earnings growth rate

14.2%

EPS growth rate

Healthcare earnings growth17.2%
Revenue growth rate5.1%
Future return on equity19.6%
Analyst coverage

Good

Last updated02 May 2024

Recent future growth updates

Recent updates

Elevance Health (NYSE:ELV) Has Announced A Dividend Of $1.63

Apr 25
Elevance Health (NYSE:ELV) Has Announced A Dividend Of $1.63

Elevance Health: It's Not Too Late To Buy Their Dividend Growth

Apr 23

Is Elevance Health (NYSE:ELV) Using Too Much Debt?

Apr 16
Is Elevance Health (NYSE:ELV) Using Too Much Debt?

Elevance Health: Not Doing Enough In 2024 To Justify Premium Price

Apr 11

Elevance Health, Inc.'s (NYSE:ELV) Earnings Haven't Escaped The Attention Of Investors

Apr 01
Elevance Health, Inc.'s (NYSE:ELV) Earnings Haven't Escaped The Attention Of Investors

Elevance: A Healthy Dose Of Dividend Growth

Mar 21

Elevance Heath: Financial Growth And Technical Strength Indicate A Buy

Mar 07

Elevance Health (NYSE:ELV) Will Pay A Larger Dividend Than Last Year At $1.63

Feb 19
Elevance Health (NYSE:ELV) Will Pay A Larger Dividend Than Last Year At $1.63

Elevance Health: Time To Buy This Incredible Dividend Growth Stock

Jan 26

Slowing Rates Of Return At Elevance Health (NYSE:ELV) Leave Little Room For Excitement

Jan 19
Slowing Rates Of Return At Elevance Health (NYSE:ELV) Leave Little Room For Excitement

Is Elevance Health (NYSE:ELV) A Risky Investment?

Jan 02
Is Elevance Health (NYSE:ELV) A Risky Investment?

Elevance Health, Inc.'s (NYSE:ELV) Shares Not Telling The Full Story

Dec 18
Elevance Health, Inc.'s (NYSE:ELV) Shares Not Telling The Full Story

A Look At Elevance's Margin Dynamics

Nov 23

Is It Time To Consider Buying Elevance Health, Inc. (NYSE:ELV)?

Nov 16
Is It Time To Consider Buying Elevance Health, Inc. (NYSE:ELV)?

Elevance Health: A High Conviction Defensive Blue Chip Buy

Oct 19

These 4 Measures Indicate That Elevance Health (NYSE:ELV) Is Using Debt Safely

Oct 04
These 4 Measures Indicate That Elevance Health (NYSE:ELV) Is Using Debt Safely

Elevance: Pave The Way For The Next UnitedHealth

Sep 21

Elevance Health (NYSE:ELV) Is Experiencing Growth In Returns On Capital

Sep 18
Elevance Health (NYSE:ELV) Is Experiencing Growth In Returns On Capital

Here's The Price I Would Buy Elevance Health Stock

Sep 13

If EPS Growth Is Important To You, Elevance Health (NYSE:ELV) Presents An Opportunity

Aug 18
If EPS Growth Is Important To You, Elevance Health (NYSE:ELV) Presents An Opportunity

Is Now The Time To Look At Buying Elevance Health, Inc. (NYSE:ELV)?

Aug 04
Is Now The Time To Look At Buying Elevance Health, Inc. (NYSE:ELV)?

Narrowing Down High-Quality Dividend Growth: Elevance Health Is Elemental

Jul 24

Elevance Health: Beaten Down Share Price Offers Solid Potential

Jul 10

Here's Why Elevance Health (NYSE:ELV) Can Manage Its Debt Responsibly

Jul 05
Here's Why Elevance Health (NYSE:ELV) Can Manage Its Debt Responsibly

Elevance Health: A Critical Update (Rating Downgrade)

Jun 05

Elevance Health's (NYSE:ELV) Returns On Capital Are Heading Higher

Jun 04
Elevance Health's (NYSE:ELV) Returns On Capital Are Heading Higher

Is Now The Time To Look At Buying Elevance Health, Inc. (NYSE:ELV)?

May 05
Is Now The Time To Look At Buying Elevance Health, Inc. (NYSE:ELV)?

We Think Elevance Health (NYSE:ELV) Can Stay On Top Of Its Debt

Apr 04
We Think Elevance Health (NYSE:ELV) Can Stay On Top Of Its Debt

Elevance Health's (NYSE:ELV) Dividend Will Be Increased To $1.48

Feb 17
Elevance Health's (NYSE:ELV) Dividend Will Be Increased To $1.48

Elevance Health (NYSE:ELV) Is Experiencing Growth In Returns On Capital

Feb 13
Elevance Health (NYSE:ELV) Is Experiencing Growth In Returns On Capital

Elevance Health: Attractive On Its Expansion Catalysts

Feb 09

Elevance Health (NYSE:ELV) Has Announced That It Will Be Increasing Its Dividend To $1.48

Jan 28
Elevance Health (NYSE:ELV) Has Announced That It Will Be Increasing Its Dividend To $1.48

Elevance Health acquiring Blue Cross and Blue Shield of Louisiana

Jan 23

Elevance Health Offers Great Value

Jan 17

At US$483, Is Elevance Health Inc. (NYSE:ELV) Worth Looking At Closely?

Jan 17
At US$483, Is Elevance Health Inc. (NYSE:ELV) Worth Looking At Closely?

Elevance Health: Strong And Steady EPS Growth Ahead, High Relative Strength Name

Jan 02

Elevance Health (NYSE:ELV) Seems To Use Debt Rather Sparingly

Nov 28
Elevance Health (NYSE:ELV) Seems To Use Debt Rather Sparingly

Does Elevance Health (NYSE:ELV) Deserve A Spot On Your Watchlist?

Nov 16
Does Elevance Health (NYSE:ELV) Deserve A Spot On Your Watchlist?

Elevance Health to acquire speciality pharmacy from CarepathRx

Nov 09

Elevance Health (NYSE:ELV) Is Doing The Right Things To Multiply Its Share Price

Nov 02
Elevance Health (NYSE:ELV) Is Doing The Right Things To Multiply Its Share Price

Elevance Health declares $1.28 dividend

Oct 19

Are Investors Undervaluing Elevance Health Inc. (NYSE:ELV) By 37%?

Oct 12
Are Investors Undervaluing Elevance Health Inc. (NYSE:ELV) By 37%?

Elevance affiliates to offer affordable Medicare Advantage plans

Oct 10

Molina, Elevance, Centene win Medicare contracts in California

Aug 26

Elevance Health (NYSE:ELV) Seems To Use Debt Rather Sparingly

Aug 25
Elevance Health (NYSE:ELV) Seems To Use Debt Rather Sparingly

Elevance Health: Continues To Grow, A Strong Buy

Aug 18

What Does Elevance Health Inc.'s (NYSE:ELV) Share Price Indicate?

Aug 13
What Does Elevance Health Inc.'s (NYSE:ELV) Share Price Indicate?

Elevance Health (NYSE:ELV) Shareholders Will Want The ROCE Trajectory To Continue

Aug 01
Elevance Health (NYSE:ELV) Shareholders Will Want The ROCE Trajectory To Continue

Earnings and Revenue Growth Forecasts

NYSE:ELV - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026195,0879,97910,46210,8056
12/31/2025182,3769,09210,06412,54512
12/31/2024171,5658,0428,7208,16512
3/31/2024171,7456,2442,2963,570N/A
12/31/2023171,3405,9876,7658,061N/A
9/30/2023168,6266,1278,2469,514N/A
6/30/2023165,7166,44110,57111,825N/A
3/31/2023160,6766,09411,12812,327N/A
12/31/2022156,5995,8947,2478,399N/A
9/30/2022153,2516,16610,39511,589N/A
6/30/2022149,1346,0728,0229,169N/A
3/31/2022144,3536,2287,2638,400N/A
12/31/2021138,6436,1587,2778,364N/A
9/30/2021133,8835,5189,48010,505N/A
6/30/2021129,2194,2315,7786,851N/A
3/31/2021124,6324,7149,65710,678N/A
12/31/2020121,8684,5729,66710,688N/A
9/30/2020117,4494,9557,1088,202N/A
6/30/2020112,9655,9169,96011,019N/A
3/31/2020109,1674,7795,8996,946N/A
12/31/2019104,2124,8074,9846,061N/A
9/30/2019100,1654,2984,1515,197N/A
6/30/201996,7424,0743,0074,137N/A
3/31/201994,2203,9892,0183,242N/A
12/31/201892,0913,7502,6193,827N/A
9/30/201891,4094,5568912,063N/A
6/30/201890,5844,3442,8253,861N/A
3/31/201890,0614,1452,8223,712N/A
12/31/201790,0493,843N/A4,185N/A
9/30/201789,0552,980N/A5,763N/A
6/30/201788,0382,851N/A4,322N/A
3/31/201787,0832,777N/A4,599N/A
12/31/201684,8622,470N/A3,270N/A
9/30/201683,3642,282N/A3,943N/A
6/30/201681,8662,319N/A3,322N/A
3/31/201680,4122,398N/A3,825N/A
12/31/201579,1582,560N/A4,212N/A
9/30/201577,9592,886N/A3,472N/A
6/30/201576,6052,862N/A3,734N/A
3/31/201575,0662,734N/A3,632N/A
12/31/201473,8862,560N/A3,369N/A
9/30/201472,7922,362N/A3,337N/A
6/30/201472,0902,385N/A4,129N/A
3/31/201471,3072,453N/A3,483N/A
12/31/201371,0242,634N/A3,052N/A
9/30/201368,4432,785N/A3,539N/A
6/30/201365,9412,823N/A2,382N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ELV's forecast earnings growth (12.4% per year) is above the savings rate (2.4%).

Earnings vs Market: ELV's earnings (12.4% per year) are forecast to grow slower than the US market (14.2% per year).

High Growth Earnings: ELV's earnings are forecast to grow, but not significantly.

Revenue vs Market: ELV's revenue (5.1% per year) is forecast to grow slower than the US market (8.2% per year).

High Growth Revenue: ELV's revenue (5.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ELV's Return on Equity is forecast to be low in 3 years time (19.6%).


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.